OCULAR THERAPEUTIX, INC Debt Securities, Available-for-sale, Amortized Cost
OCULAR THERAPEUTIX, INC (OCUL) had Debt Securities, Available-for-sale, Amortized Cost of $3.00 million as of 2017-06-30, per its 10-Q filed 2017-08-08.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2018-03-08
- 2017-06-30: Debt Securities, Available-for-sale, Amortized Cost $3.00M.
- 2017-03-31: Debt Securities, Available-for-sale, Amortized Cost $25.71M.
- 2016-12-31: Debt Securities, Available-for-sale, Amortized Cost $35.22M.
- 2016-09-30: Debt Securities, Available-for-sale, Amortized Cost $23.51M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2017-06-30 | $3.00M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $25.71M 10-Q · filed 2017-05-05 |
| 2016-12-31 | $35.22M 10-K · filed 2018-03-08 |
| 2016-09-30 | $23.51M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $35.71M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $49.24M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $74.35M 10-K · filed 2017-03-10 |
| 2015-09-30 | $72.46M 10-Q · filed 2015-11-10 |
| 2015-06-30 | $45.04M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $54.90M 10-Q · filed 2015-05-15 |
| 2014-12-31 | $37.44M 10-K · filed 2016-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |